ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
April 16 2024 - 4:05PM
ClearPoint Neuro Congratulates its Partner AviadoBio on First
Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101
for Frontotemporal Dementia with GRN Mutations
ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global
device, cell, and gene therapy-enabling company offering precise
navigation to the brain and spine, today congratulates its partner
AviadoBio on treating its first patient in the ASPIRE-FTD Phase 1/2
clinical trial evaluating its investigational gene therapy AVB-101
in people with frontotemporal dementia (FTD) with progranulin (GRN)
mutations.
“FTD is an important cause of dementia in people under 65 and
has a devastating impact on patients and families. The importance
of accurately delivering this one-time gene therapy to the
thalamus, while minimizing systemic exposure, is the precise use
case of ClearPoint’s minimally invasive platform for gene and cell
delivery,” stated Jeremy Stigall, Chief Business Officer at
ClearPoint Neuro. “We are proud to support AviadoBio and the team
at Mazowiecki Szpital Bródnowski Hospital, as well as other
clinical trial sites to come in Europe and the United States.”
More information about the ASPIRE-FTD study can be found at
https://clinicaltrials.gov/study/NCT06064890.
About Frontotemporal Dementia with Progranulin Mutations
(FTD-GRN)
FTD is a devastating form of early-onset dementia that typically
leads to death within seven to 13 years of symptom onset and three
to 10 years from diagnosis.1,2 People with FTD commonly experience
personality changes, behavioral disturbance, loss of language,
apathy, and reduced mobility.3
FTD is a leading cause of dementia in people under the age of
654 with an estimated prevalence at any one time of up to 4.6 cases
per 1,000 people.5 FTD typically strikes younger than Alzheimer’s
disease and the majority of FTD cases occur between 45 and 68 years
of age.6,7 Given the early onset, FTD can have a substantially
greater impact on work, family, and finances than Alzheimer’s
disease.8 Genetic FTD cases account for about one-third of cases
and are associated with autosomal dominant mutations in three
genes, including the GRN (progranulin) gene.9 Approximately 11,000
people in the U.S. and EU5 are living with FTD-GRN with
approximately 2,200 new cases per year. 1,10 Some FTD cases may be
misidentified, and diagnostic delay is common. As disease
education, genetics knowledge, and research and treatment options
grow, these numbers are expected to increase.
________________________1 Onyike CU. Neuroepidemiology.
2011;37:166–1672 Riedl L et al. Neuropsychiatr Dis Treat.
2014;10:297–3103 Pressman P and Miller BL. Biol Psychiatry.
2014;75(7):574–5814 Hendriks S, Peetoom K, Bakker C, et al. Global
Prevalence of Young-Onset Dementia: A Systematic Review and
Meta-analysis. JAMA Neurol. 2021;78(9):1080–1090.
doi:10.1001/jamaneurol.2021.216 5 Hogan DB et al. Can J Neurol Sci.
2016;43 (Suppl 1):S96–S1096 Moore KM et al. Lancet Neurol.
19(2):145–1567 Kansal K et al. Dement Geriatr Cogn Disord.
2016;41:109–1228 Galvin JE et al. Neurology. 89(20):2049–20569
Young JJ et al. Ther Adv Psychopharmacol. 2018;8(1):33–48 10 Kuang,
L., et. al. Frontotemporal dementia non-sense mutation of
progranulin rescued by aminoglycosides. Human Molecular Genetics
2020;29(4):624-634About ClearPoint Neuro
ClearPoint Neuro is a device, cell, and gene
therapy-enabling company offering precise navigation to the brain
and spine. The Company uniquely provides both established clinical
products as well as pre-clinical development services for
controlled drug and device delivery. The Company’s flagship
product, the ClearPoint Neuro Navigation System, has FDA clearance
and is CE-marked. ClearPoint Neuro is engaged with healthcare and
research centers in North America, Europe, Asia, and South America.
The Company is also partnered with the most innovative
pharmaceutical/biotech companies, academic centers, and contract
research organizations, providing solutions for direct CNS delivery
of therapeutics in pre-clinical studies and clinical trials
worldwide. To date, thousands of procedures have been performed and
supported by the Company’s field-based clinical specialist team,
which offers support and services to our customers and partners
worldwide. For more information, please visit
www.clearpointneuro.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the context of the federal securities laws, which
may include the Company’s expectation for the future market of its
products and services, and other performance and results. These
forward-looking statements are based on management’s current
expectations and are subject to the risks inherent in the business,
which may cause the Company's actual results to differ materially
from those expressed in or implied by forward-looking statements.
Particular uncertainties and risks include those relating to:
global and political instability, supply chain disruptions, labor
shortages, and macroeconomic and inflationary conditions; future
revenue from sales of the Company’s products and services; the
Company’s ability to market, commercialize and achieve broader
market acceptance for new products and services offered by the
Company; the ability of our biologics and drug delivery partners to
achieve commercial success, including their use of the Company’s
products and services in their delivery of therapies; the Company’s
expectations, projections and estimates regarding expenses, future
revenue, capital requirements, and the availability of and the need
for additional financing; the Company’s ability to obtain
additional funding to support its research and development
programs; the ability of the Company to manage the growth of its
business; the Company’s ability to attract and retain its key
employees; and risks inherent in the research, development, and
regulatory approval of new products. More detailed information on
these and additional factors that could affect the Company’s actual
results are described in the “Risk Factors” section of the
Company’s Annual Report on Form 10-K for the year ended December
31, 2023, which has been filed with the Securities and Exchange
Commission. The Company does not assume any obligation to update
these forward-looking statements.